Indirect CD133 MicroBead Kit ( #130-091-895 )

Indirect CD133 MicroBead Kit

Description

The Indirect CD133 MicroBead Kit was developed for positive selection or depletion of CD133⁺ cells, using a two-step procedure involving indirect magnetic labeling.

Hematopoietic stem cells can be isolated from peripheral blood, cord blood, bone marrow, or leukapheresis product.
Neural progenitor cells can be isolated from single-cell suspensions from primary neural tissues or cell lines.
ES and iPS cell–derived neural, endothelial, or hematopoietic progenitors can be isolated from differentiated ES or iPS cell cultures¹.
Cancer stem cells can be isolated from single-cell suspensions from primary tumor tissue or cell lines.

Applications

Background information
CD133, formerly known as AC133, recognizes epitope 1 of the CD133 antigen.^2,3 It is a marker that is frequently found on multipotent progenitor cells, including immature hematopoietic stem and progenitor cells. In the hematopoietic system, CD133 is expressed on a small portion of CD34^–cells⁴ as well as on a subset of CD34^bright stem and progenitor cells in human fetal liver, bone marrow, cord blood, and peripheral blood⁵. CD133 has also been found to be expressed on circulating endothelial progenitor cells;^6,7 fetal neural stem cells;^8,9 other tissue-specific stem cells, such as renal¹⁰, prostate¹¹, and corneal¹² stem cells; cancer stem cells from tumor tissues; as well as ES and iPS cell-derived cells.

There is a growing interest in CD133 antigen expressing stem cells from normal blood or bone marrow in the field of regenerative medicine, for example bone marrow-derived CD133⁺ stem cells in cardiovascular^13-17, liver, or peripheral artery diseases^18-20.

The CD133 antibody included in the kit recognizes epitope CD133/1. For quality control staining of CD133-separated cells, the use of CD133/2 (293C3)-PE or -APC is recommended.

Downstream applications
Isolated from hematopoietic sources, CD133⁺ cells can become adherent and are reported to become CD133-negative during culture.^21,22 These adherent cells can then in turn give rise to nonadherent CD133⁺ cells that are able to differentiate to both hematopoietic and nonhematopoietic cell types.²³
CD133⁺ cells have shown a capacity for tissue differentiation, including to neural lineages²⁴. CD133⁺ isolated from fetal liver²⁵, umbilical cord blood²⁶, bone marrow²⁷, mobilized blood²⁸, and skin²⁹ are capable of in vitro differentiation to neuronal cells as well as to astrocytes,^25,26,28 oligodendrocytes,^26,28 and glial cells.²⁶ CD133⁺ cells isolated from human fetal brain^8,9,30-32 were able to form self-renewing neurospheres in vitro, and to differentiate into neurons^8,32 and glia^19,23. When injected into mice, human CD133⁺ cells differentiated into fully integrated neurones and glial cells^9,30 as well as astrocytes and endothelial cells²⁹. The CD34⁺CD133⁺ cell population, which includes CD34⁺CD38^– cells, was shown to be capable of repopulating NOD/SCID mice³³.

Columns

For positive selection: MS, LS, XS, or autoMACS® Columns. For depletion: LD, CS, D or autoMACS® Columns

Clone	Isotype
AC133	Mouse IgG1

Figure 1

Separation of non-mobilized PBMCs using CD133/1 (AC133)-Biotin, Anti-Biotin MicroBeads, MS Columns, and a MiniMACS™ Separator. The cells are fluorescently stained with CD34-FITC and CD133/2 (293C3)-PE. Cell debris and dead cells were excluded from the analysis based on scatter signals and PI fluorescence.

Before separation

CD133⁺ cells